By Stephen NakrosisShares of biotechnology company Selecta Biosciences Inc. are trading lower in Wednesday's late-session, after the company said the U.S. Food and Drug Administration placed a clinical hold on its Phase 1/2 clinical trial of SEL-302 to treat patients with methylmalonic acidemia. The company said SEL-302 consists of MMA-101 plus ImmTOR. Selecta Biosciences also said on Nov. 23 it received a letter from the FDA "issuing a clinical hold in order to obtain additional information on the chemistry, manufacturing and controls related to the MMA-101 product candidate." ET, shares of Selecta Biosciences were trading 13.2% lower at $2.76 a share. Write to Stephen Nakrosis at firstname.lastname@example.org(END) Dow Jones NewswiresNovember 24, 2021 18:08 ET (23:08 GMT)Copyright (c) 2021 Dow Jones & Company, Inc.
Source: Wall Street Journal November 25, 2021 05:13 UTC